About
Nutromics is an Australian healthcare technology company founded in 2017, focused on revolutionizing healthcare through Continuous Molecular Monitoring (CMM). Headquartered in Melbourne, with an R&D facility in San Diego, the company employs over 50 people and has raised around USD 30 million in funding. Nutromics aims to achieve zero preventable deaths by providing personalized and timely molecular insights. The company has developed a pioneering medical wearable device, a patch that combines a microneedle array and DNA-based sensor technology. This "lab-on-a-patch®" allows for continuous, real-time molecular monitoring by converting molecular signals into electrical signals that are transmitted via Bluetooth to clinicians. Nutromics is currently working on a continuous monitor for the intravenous antibiotic vancomycin, with plans for FDA approval in 2025, and is advancing a pipeline of new DNA sensors for various clinical applications. Their technology is designed to enhance patient outcomes and reduce healthcare costs by enabling dynamic monitoring of conditions that require trend data for effective treatment.
Technologies
Keywords
Company Information
- Employees63
- Founded2017
- Total Funding$29122998
Location
420 Victoria St, Melbourne, Victoria, Australia, 3051
